Advances in adrenocortical carcinoma pharmacotherapy: what is the current state of the art?
V Cremaschi, A Abate, D Cosentini… - Expert Opinion on …, 2022 - Taylor & Francis
Introduction Surgery, followed or not by adjuvant mitotane, is the current mainstay of therapy
for patients with early-stage adrenocortical carcinoma (ACC). Mitotane, either alone or in …
for patients with early-stage adrenocortical carcinoma (ACC). Mitotane, either alone or in …
Advances in adrenocortical carcinoma pharmacotherapy: what is the current state of the art?
V Cremaschi, A Abate, D Cosentini, S Grisanti… - EXPERT OPINION ON …, 2022 - iris.unibs.it
Introduction: Surgery, followed or not by adjuvant mitotane, is the current mainstay of therapy
for patients with early-stage adrenocortical carcinoma (ACC). Mitotane, either alone or in …
for patients with early-stage adrenocortical carcinoma (ACC). Mitotane, either alone or in …
Advances in adrenocortical carcinoma pharmacotherapy: what is the current state of the art?
V Cremaschi, A Abate, D Cosentini… - Expert opinion on …, 2022 - pubmed.ncbi.nlm.nih.gov
Introduction Surgery, followed or not by adjuvant mitotane, is the current mainstay of therapy
for patients with early-stage adrenocortical carcinoma (ACC). Mitotane, either alone or in …
for patients with early-stage adrenocortical carcinoma (ACC). Mitotane, either alone or in …
Advances in adrenocortical carcinoma pharmacotherapy: what is the current state of the art?
V Cremaschi, A Abate, D Cosentini… - Expert Opinion on …, 2022 - europepmc.org
Surgery, followed or not by adjuvant mitotane, is the current mainstay of therapy for patients
with early-stage adrenocortical carcinoma (ACC). Mitotane, either alone or in association …
with early-stage adrenocortical carcinoma (ACC). Mitotane, either alone or in association …